Heterocyclic MAGL Inhibitors That Elevate 2-Arachidonoylglycerol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroinflammation, neurodegenerative diseases, pain, cancer, and mental disorders lack effective inhibitors for monoacylglycerol lipase (MAGL), which are crucial for modulating neuroinflammation and associated pathologies.
Innovation Solution
Development of heterocyclic compounds that act as MAGL inhibitors, formulated as pharmaceutical compositions to inhibit MAGL activity and increase levels of 2-arachidonoylglycerol, thereby reducing neuroinflammation and associated conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neuroinflammation and neurodegenerative diseases, then existing therapeutic options are available, but effective MAGL inhibition is lacking
Solution Approach 1:
The patent segments the therapeutic approach by developing specific heterocyclic compound structures (formula I) that selectively target MAGL enzyme, separating this specific inhibition capability from general anti-inflammatory treatments. The segmented molecular design allows precise interaction with MAGL while maintaining other therapeutic properties.
Solution Approach 2:
The heterocyclic compounds of formula (I) act as intermediary substances that mediate between the administered drug and the MAGL enzyme. These compounds specifically bind to MAGL, inhibiting its activity and thereby increasing 2-AG levels, which in turn exerts therapeutic effects on neuroinflammation and related conditions.
2Object-affected harmful factors
If MAGL activity is inhibited to increase 2-AG levels, then neuroinflammation is reduced, but new pharmaceutical compounds must be developed
Solution Approach 1:
The patent applies parameter changes by modifying molecular structures within formula (I) through varying substituents R1-R6, R8-R12, and ring structures A1-A6. This systematic parameter variation allows optimization of MAGL inhibition potency, selectivity, and pharmacokinetic properties while maintaining the core inhibitory mechanism.
Solution Approach 2:
The heterocyclic compounds represent composite molecular structures combining multiple functional groups and heterocyclic rings in specific configurations. This composite design integrates MAGL binding moieties with pharmacophoric elements, creating molecules that achieve both specific enzyme inhibition and desired therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit MAGL, increasing 2-arachidonoylglycerol levels, providing therapeutic benefits for neuroinflammation, neurodegenerative diseases, pain, cancer, and mental disorders, including multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, and chemotherapy-induced neuropathy.
Implementation Method 1
The compounds effectively inhibit MAGL, increasing 2-arachidonoylglycerol levels
Data Source
AI summary
The invention provides new heterocyclic compounds having the general formula (I)wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.